Sobi increases 2025 financial outlook following 21% surge in Q3 revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Source: SeekingAlpha
Financial Performance: Swedish Orphan Biovitrum AB (Sobi) upgraded its full-year 2025 financial outlook following a strong Q3 performance, reporting a 21% increase in Q3 revenue to SEK 7,776 million and a year-to-date revenue of SEK 20,417 million, up 15%.
Strategic Developments: The company received European approval for Tryngolza, targeting a market exceeding SEK 5 billion by 2026, while also recording a non-cash impairment charge of SEK 6,612 million for Vonjo, which will not affect cash flow.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
